77 related articles for article (PubMed ID: 31110205)
1. Regulatory mechanism of interaction between Y-box-binding protein 1 and heterogenous nuclear ribonucleoprotein K in cell division cycle 25a signal pathway and lung cancer metastasis.
Fu L; Yang M; Ma Y
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):62-68. PubMed ID: 38279484
[TBL] [Abstract][Full Text] [Related]
2. HNRNPK/CLCN3 axis facilitates the progression of LUAD through CAF-tumor interaction.
Li Y; Yang Y; Ma Q; Cheng H; Wang H; Ma C; Li F; Zhao S; Li X; Qi Y; Gu Z
Int J Biol Sci; 2022; 18(16):6084-6101. PubMed ID: 36439880
[No Abstract] [Full Text] [Related]
3. Role of Heterogeneous Nuclear Ribonucleoproteins in the Cancer-Immune Landscape.
Sudhakaran M; Doseff AI
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982162
[TBL] [Abstract][Full Text] [Related]
4. SDCBP-AS1 destabilizes β-catenin by regulating ubiquitination and SUMOylation of hnRNP K to suppress gastric tumorigenicity and metastasis.
Han J; Nie M; Chen C; Cheng X; Guo T; Huangfu L; Li X; Du H; Xing X; Ji J
Cancer Commun (Lond); 2022 Nov; 42(11):1141-1161. PubMed ID: 36209503
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Qian W; Zhao M; Wang R; Li H
J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
[TBL] [Abstract][Full Text] [Related]
6. eNEMAL, an enhancer RNA transcribed from a distal MALAT1 enhancer, promotes NEAT1 long isoform expression.
Stone JK; Vukadin L; Ahn EE
PLoS One; 2021; 16(5):e0251515. PubMed ID: 34019552
[TBL] [Abstract][Full Text] [Related]
7. Splicing Factor Transcript Abundance in Saliva as a Diagnostic Tool for Breast Cancer.
Bentata M; Morgenstern G; Nevo Y; Kay G; Granit Mizrahi A; Temper M; Maimon O; Monas L; Basheer R; Ben-Hur A; Peretz T; Salton M
Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32756364
[TBL] [Abstract][Full Text] [Related]
8. Identification of Long Noncoding RNAs as Predictors of Survival in Triple-Negative Breast Cancer Based on Network Analysis.
Li XX; Wang LJ; Hou J; Liu HY; Wang R; Wang C; Xie WH
Biomed Res Int; 2020; 2020():8970340. PubMed ID: 32190687
[TBL] [Abstract][Full Text] [Related]
9. Post-translational modification control of RNA-binding protein hnRNPK function.
Xu Y; Wu W; Han Q; Wang Y; Li C; Zhang P; Xu H
Open Biol; 2019 Mar; 9(3):180239. PubMed ID: 30836866
[TBL] [Abstract][Full Text] [Related]
10. The emerging roles of hnRNPK.
Wang Z; Qiu H; He J; Liu L; Xue W; Fox A; Tickner J; Xu J
J Cell Physiol; 2020 Mar; 235(3):1995-2008. PubMed ID: 31538344
[TBL] [Abstract][Full Text] [Related]
11. hnRNPK S379 phosphorylation participates in migration regulation of triple negative MDA-MB-231 cells.
Tsai HY; Fu SL; Tseng LM; Chiu JH; Lin CH
Sci Rep; 2019 May; 9(1):7611. PubMed ID: 31110205
[TBL] [Abstract][Full Text] [Related]
12. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition
Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ
Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
14. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
15. FGD5-AS1 facilitates glioblastoma progression by activation of Wnt/β-catenin signaling via regulating miR-129-5p/HNRNPK axis.
Wu L; Zhu X; Song Z; Guo M; Liang J; Yan D
Life Sci; 2020 Sep; 256():117998. PubMed ID: 32585241
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
